Vai al contenuto
AwardGraph

Profilo fornitore

Macure Pharma ApS

DK
Aggiudicazioni
13
Valore totale aggiudicato
2.403.902 €
Paesi
Danimarca, Finlandia
Ultima aggiudicazione
24 feb 2026
In scadenza entro 12 mesi
1

Storico delle aggiudicazioni

DataCommittenteTitoloCategoriaImportoPaeseScadenzaFonte
24/02/2026Amgros I/SDenmark – Pharmaceutical products – Amgros 2026 1.296.aDK31/03/2028Vedi su TED
30/01/2026Pohjois-Pohjanmaan hyvinvointialueFinland – Medical equipments, pharmaceuticals and personal care products – Lorazepam Macure 2mg/ml-​valmiste ajalle 1.2.2026-​31.12.20271,0 €FI31/12/2027Vedi su TED
30/01/2026Pohjois-Pohjanmaan hyvinvointialueFinland – Medical equipments, pharmaceuticals and personal care products – Pentamidine Tillomed (pentamidiini)-​valmisteen valinta ajalle 1.1.2026-​31.12.2027 Pohteen lääkehankintarenkaalle1,0 €FI31/12/2027Vedi su TED
27/11/2025Amgros I/SDenmark – Pharmaceutical products – Amgros 2026 1.607.aDK31/03/2029Vedi su TED
03/11/2025Amgros I/SDenmark – Pharmaceutical products – Amgros 2026 2.1302.bProdotti farmaceuticiDK31/03/2029Vedi su TED
17/10/2025Amgros I/SDenmark – Pharmaceutical products – Amgros 2026 2.3.bDK31/03/2029Vedi su TED
05/11/2024Amgros I/SDenmark – Pharmaceutical products – Amgros 2025 2.1310.bDK31/03/2028Vedi su TED
28/10/2024Amgros I/SDenmark – Pharmaceutical products – Amgros 2025 2.3.bDK31/03/2028Vedi su TED
25/10/2024Amgros I/SDenmark – Pharmaceutical products – Amgros 2025 1.1390.bDK31/03/2028Vedi su TED
24/10/2024Amgros I/SDenmark – Pharmaceutical products – Amgros 2025 1.1204.bDK31/03/2028Vedi su TED
09/08/2024Sansia OyFinland – Medical equipments, pharmaceuticals and personal care products – Lääkevalmisteet sekä niihin rinnastettavat valmisteet Itä-Suomen yhteistyöalueelle403,9K €FIVedi su TED
25/06/2024Amgros I/SDenmark – Pharmaceutical products – Amgros 2024 1.342.bDK31/03/2027Vedi su TED
08/03/2024Pohjois-Pohjanmaan hyvinvointialueFinland – Pharmaceutical products – Lääkevalmisteet ja niihin rinnastettavat tuotteet täydentävä kilpailutus ajalle 1.3.-31.12.2024 + optiovuosi 20252,0 Mln €FIVedi su TED